Anteotech Ltd · ASX:ADO
Anteotech — Investor Presentation (March 2021)
8 slides from Anteotech's investor presentation, Mar 22, 2021
Slide 1: ASX Announcement: InvestorStream Interview - Presentation
ASX Announcement For personal use only 22 March 2021 InvestorStream Interview - Presentation AnteoTech Ltd (ASX: ADO) (“AnteoTech” or “the Company”) is pleased to provide a copy of the presentation by CEO Derek Thomson for the InvestorStream interview. The interview is available at: https://www.inve
Slide 2: Investor Stream Interview: Life Science Timeline - CE Mark and Beyond
For personal use only Investor Stream Interview Life Science Timeline - CE Mark and Beyond AnteoTech Ltd (ASX:ADO) Derek Thomson, CEO 22 March 2021 1
Slide 3: AnteoTech Investor Highlights
ANTEOTECH INVESTOR HIGHLIGHTS Diversified investment opportunity with high growth potential in high impact sectors For personal use only Unique, proprietary nano- Proven product AnteoBind in market – Integrated in Ellume Home Test - FDA EUA polymer technology Proof of concept delivered across Life S
Slide 4: What Sets AnteoTech's Technology Apart
WHAT SETS ANTEOTECH’S TECHNOLOGY APART Combining AnteoBind technology with activated Europium achieves the For personal use only high sensitivity needed for COVID-19 • COVID-19 Antigen Rapid Test uses • Very high dynamic signal range and AnteoBind activated Europium intensity2 • Consistent gentle bi
Slide 5: Anticipated Development Timeline 2021
ANTICIPATED DEVELOPMENT TIMELINE 2021 For personal use only 2021 1 JAN FEB MAR APR MAY JUN JUL AUG SEP Operon1 Lab Trial EU CE Mark 3 EU CE Mark AnteoTech COVID-19 ART manufacturing scale Updated VIDRL 2 Submission up EU Market Launch Clinical Trials AU TGA + COVID-19 Saliva - Saliva Submission Revi
Slide 6: AnteoBind & Lateral Flow Test Principles
ANTEOBIND & LATERAL FLOW TEST PRINCIPLES For personal use only Protein-Particle Conjugate for detection Lateral Flow Test Model in the test is the key component that impacts Analyte Sample pad Conjugate pad Membrane Test line Control line Wick an assay performance Imaging of an antibody conjugated,
Slide 7: Global Challenge of Sepsis
GLOBAL CHALLENGE OF SEPSIS For personal use only • Sepsis: preventable, life-threating condition marked by severe organ dysfunction. • 2017 studies estimate 49 million cases and 11 million sepsis-related deaths worldwide; ~ 20% accounting for 20% of all global deaths global deaths due to sepsis • Ea
Slide 8: Leveraging Current Development
LEVERAGING CURRENT DEVELOPMENT Investment in the current test platform could instigate a number For personal use only of leverage plays that will accelerate revenue Test suite enabled on different reader platforms designed for market segments Current Tests • In field testing – military / refugee / c